© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
MPNs
Challenges Remain in the Treatment Landscape for Myelofibrosis
April 04, 2020
Ruben Mesa, MD, discusses the current challenges in the treatment landscape for researchers treating myelofibrosis (MF) and how a greater understanding of why patients relapse will help investigators overcome these challenges.
Expert Addresses Challenges Associated With Allogeneic Transplant in Myelofibrosis
March 25, 2020
In an interview with Targeted Oncology, Tania Jain, MBBS, discussed the role of transplant as treatment of patients with myelofibrosis and the challenges that remain in this space. She also spoke to the treatment options for patients with graft-versus-host-disease.
Fedratinib and Ruxolitinib Improve Survival as Treatment of Myelofibrosis
March 24, 2020
Ruben Mesa, MD, discusses the role of ruxolitinib and fedratinib, first-generation JAK inhibitors, as treatment of patients with myelofibrosis.
Management Strategies Set for Varying Patterns of Ruxolitinib Progression in Myelofibrosis
March 19, 2020
A report from the Canadian Myeloproliferative Neoplasm Group has outlined different patterns of treatment failure from JAK inhibitor therapy in patients with myelofibrosis. The report, published in JCO Oncology Practice, suggests management practices for each pattern of response.
Novel Agent Receives FDA Orphan Drug Designation for GVHD
March 18, 2020
The FDA has granted 2 orphan drug designations to ALPN-101 for both the prevention and treatment of acute graft-versus-host disease, according to a press release from Alpine Immune Sciences.
Ruxolitinib Effective for Long-Term Treatment of Polycythemia Vera After Hydroxyurea
March 18, 2020
Ruxolitinib was found to be safe and effective for long-term treatment of patients with polycythemia vera who are resistant to or intolerant of hydroxyurea, according to the 5-year follow-up data from the phase III RESPONSE trial, recently published in The Lancet Haematology.
Ropeginterferon Alfa-2b Appears Effective in Polycythemia Vera Without Splenomegaly
March 17, 2020
Ropeginterferon alfa-2b improved responses overtime in patients with polycythemia vera who presented predominantly without splenomegaly compared with hydroxyurea, according to findings from the phase III PROUD-PV clinical trial and its extension study, CONTINUATION-PV.
The Role of Ruxolitinib in Myeloproliferative Neoplasms
February 29, 2020
Jorge E. Cortes, MD, explains how ruxolitinib is used to treat various myeloproliferative neoplasms and which patients require other therapies.
New Data May Significantly Improve Options for Myelofibrosis Therapy Following Ruxolitinib Failure
February 28, 2020
At the 24th Annual International Congress on Hematologic Malignancies, host by Physicians’ Education Resourceâ, LLC, Ruben Mesa, MD, who is director of the UT San Antonio MD Anderson Cancer Center, presented available and emerging therapy options for patients who require additional MF therapy following ruxolitinib.
Luspatercept Lowers the Transfusion Burden in Patients With Myelofibrosis-Associated Anemia
February 19, 2020
Aaron Gerds, MD discusses the results of a phase II BELIEVE study of luspatercept as treatment of patients with myelofibrosis-associated anemia.